DE3576345D1 - N-6- und 5'-n-substituierte carboxamidoadenosinderivate als herzvasodilatatoren und antihypertensive stoffe und verfahren zur herstellung dieser verbindungen. - Google Patents

N-6- und 5'-n-substituierte carboxamidoadenosinderivate als herzvasodilatatoren und antihypertensive stoffe und verfahren zur herstellung dieser verbindungen.

Info

Publication number
DE3576345D1
DE3576345D1 DE8585903162T DE3576345T DE3576345D1 DE 3576345 D1 DE3576345 D1 DE 3576345D1 DE 8585903162 T DE8585903162 T DE 8585903162T DE 3576345 T DE3576345 T DE 3576345T DE 3576345 D1 DE3576345 D1 DE 3576345D1
Authority
DE
Germany
Prior art keywords
carboxamidoadenosin
vasodilators
heart
derivatives
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585903162T
Other languages
English (en)
Inventor
A Olsson
D Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aderis Pharmaceuticals Inc
Original Assignee
Whitby Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitby Research Inc filed Critical Whitby Research Inc
Application granted granted Critical
Publication of DE3576345D1 publication Critical patent/DE3576345D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE8585903162T 1984-06-28 1985-06-19 N-6- und 5'-n-substituierte carboxamidoadenosinderivate als herzvasodilatatoren und antihypertensive stoffe und verfahren zur herstellung dieser verbindungen. Expired - Lifetime DE3576345D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62545084A 1984-06-28 1984-06-28
US06/742,565 US5310731A (en) 1984-06-28 1985-06-12 N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
PCT/US1985/001135 WO1986000310A1 (en) 1984-06-28 1985-06-19 N-6 and 5'-n substituted carboxamidoadenosine derivatives as cardiac vasodilators and antihypertensive agents, and process for making said compounds

Publications (1)

Publication Number Publication Date
DE3576345D1 true DE3576345D1 (de) 1990-04-12

Family

ID=27089928

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585903162T Expired - Lifetime DE3576345D1 (de) 1984-06-28 1985-06-19 N-6- und 5'-n-substituierte carboxamidoadenosinderivate als herzvasodilatatoren und antihypertensive stoffe und verfahren zur herstellung dieser verbindungen.

Country Status (8)

Country Link
US (2) US5310731A (de)
EP (1) EP0191025B1 (de)
AU (1) AU590724B2 (de)
CA (1) CA1285557C (de)
DE (1) DE3576345D1 (de)
ES (1) ES8609359A1 (de)
IE (1) IE58495B1 (de)
WO (1) WO1986000310A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU575438B2 (en) * 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4868160A (en) * 1985-11-06 1989-09-19 Warner-Lambert Company Method of treating psychosis using N6 -substituted -5'-oxidized adenosine analogs
NL8702926A (nl) * 1986-12-15 1988-07-01 Sandoz Ag Nieuwe furanuronzuurderivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US5219840A (en) * 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
US5652366A (en) * 1990-09-25 1997-07-29 Rhone-Poulenc Rorer Pharmaceuticals Inc. DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
FR2685918B1 (fr) * 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
FR2687678B1 (fr) * 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
ATE206432T1 (de) * 1993-07-13 2001-10-15 Nasa A3 -adenosin -rezeptor agonisten
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
AU2603197A (en) 1996-04-10 1997-10-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Use of an a1 adenosine receptor agonist to treat cerebral ischaemia
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
US6048865A (en) * 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
EP1019427A4 (de) * 1997-07-29 2000-07-19 Medco Res Inc N6-substituierte adenosin-5'-uronamide als adenosin-rezeptor-modulatoren
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
EP1090022B1 (de) 1998-06-23 2003-08-06 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivate
AU4980999A (en) 1998-07-10 2000-02-01 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The A3 adenosine receptor antagonists
TWI257306B (en) * 1999-11-23 2006-07-01 Aderis Pharmaceuticals Inc Pharmaceutical composition for treating heart rhythm disturbances comprising N6-substituted-5'-(N-substituted) carboxamidoadenosines
US6784165B1 (en) * 1999-11-23 2004-08-31 Aderis Pharmaceuticals, Inc. Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
AU2001230913B2 (en) * 2000-01-14 2005-06-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methanocarba cycloalkyl nucleoside analogues
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
AU2002239277A1 (en) * 2000-11-20 2002-05-27 Cor Therapeutics, Inc. Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions and method of use thereof
US6995148B2 (en) * 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
EP2147679B1 (de) 2001-07-25 2014-06-25 Raptor Pharmaceutical, Inc. Zusammensetzungen für den Blut-Hirn-Schrankentransport
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
AU2004238217A1 (en) * 2003-04-24 2004-11-25 Aderis Pharmaceuticals, Inc. Method of treating atrial fibrillation or atrial flutter
US20050118262A1 (en) * 2003-09-17 2005-06-02 Jack Aurora Controlled release formulation
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
CA2581132A1 (en) * 2004-09-20 2006-03-30 Inotek Pharmaceuticals Corporation Purine 5'-carboxamide derivatives and their use as adenosine receptor agonists
US20060079479A1 (en) * 2004-10-13 2006-04-13 Italo Biaggioni Methods of inducing vasodilation
EP1831225A2 (de) * 2004-11-19 2007-09-12 The Regents of the University of California Entzündungshemmende pyrazolopyrimidine
EP1889198B1 (de) 2005-04-28 2014-11-26 Proteus Digital Health, Inc. Pharma-informatiksystem
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EA200870409A1 (ru) 2006-04-04 2009-04-28 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Антагонисты киназы pi3
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
MX2010007419A (es) * 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2252293B1 (de) * 2008-03-14 2018-06-27 Intellikine, LLC Kinasehemmer und verwendungsverfahren
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
EP3009436B1 (de) * 2008-07-08 2019-06-05 Intellikine, LLC Kinasehemmer und verwendungsverfahren
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) * 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US20110305751A1 (en) 2009-02-20 2011-12-15 To-Bbb Holding B.V. Glutathione-based drug delivery system
CN101857622B (zh) * 2009-04-07 2014-12-03 中国医学科学院药物研究所 一种腺苷衍生物及其制备方法和应用
WO2010129819A2 (en) 2009-05-06 2010-11-11 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
EP2507241A1 (de) 2009-12-02 2012-10-10 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosin-derivate und dendrimerkonjugate daraus
CN103002738A (zh) 2010-05-21 2013-03-27 英特利凯恩有限责任公司 用于激酶调节的化学化合物、组合物和方法
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
UA115767C2 (uk) 2011-01-10 2017-12-26 Інфініті Фармасьютікалз, Інк. Способи отримання ізохінолінонів і тверді форми ізохінолінонів
EP2678018A4 (de) 2011-02-23 2015-09-30 Intellikine Llc Kombination von kinasehemmern und verwendungen dafür
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AU2012302197B2 (en) 2011-08-29 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
RU2015115631A (ru) 2012-09-26 2016-11-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Модулирование ire1
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL128629C (de) * 1966-05-07
NL130136C (de) * 1966-10-20
SE329623B (de) * 1967-06-08 1970-10-19 C F Boehringer Soehne Gmbh
DE1670265A1 (de) * 1967-08-25 1971-01-28 Boehringer Mannheim Gmbh 2-Amino-Adenosinderivate und Verfahren zu deren Herstellung
DE2007273A1 (de) * 1970-02-18 1971-08-26 Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof N(6) Aralkyl adenosin Derivate und Verfahren zur Herstellung derselben
US4224438A (en) * 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
DE2052596A1 (de) * 1970-10-27 1972-05-04 Boehringer Mannheim Gmbh, 6800 Mannheim Neuartige Verwendung von N(6)-substituierten Adenosin-Derivaten
US4029884A (en) * 1971-03-18 1977-06-14 Abbott Laboratories Adenosine-5'-carboxylic acid amides
BE788958A (fr) * 1971-09-18 1973-03-19 Schering Ag Derives d'adenosine et leur procede de preparation
US4090021A (en) * 1971-10-08 1978-05-16 Schering Aktiengesellschaft Process for the production of N6 -substituted adenosine nucleotides and products resulting therefrom
US3864483A (en) * 1972-03-22 1975-02-04 Abbott Lab Adenosine-5{40 -carboxylic acid amides
US3966916A (en) * 1972-09-09 1976-06-29 Boehringer Mannheim G.M.B.H. N(6)-disubstituted adenoisine compounds and therapeutic compositions
US3931401A (en) * 1972-10-21 1976-01-06 Abbott Laboratories 1,N6 -etheno-5'-adenosine carboxamides for increasing coronary sinus partial pressure of oxygen
IL48854A (en) * 1975-02-18 1979-12-30 Sparamedica Ag Adenosine nitrates,their manufacture and pharmaceutical compositions containing them
LU75374A1 (de) * 1976-07-13 1978-02-08
US4167565A (en) * 1976-11-08 1979-09-11 Abbott Laboratories Adenosine-5'-carboxamides and method of use
US4514405A (en) * 1981-09-17 1985-04-30 Merck Patent Gesellschaft Mit Beschrankter Haftung Use of adenosine derivatives as anticonvulsants
JPS58167599A (ja) 1982-03-29 1983-10-03 Tanabe Seiyaku Co Ltd アデノシン誘導体及びその製法
DE3576344D1 (de) * 1984-04-18 1990-04-12 Whitby Research Inc Cardio-vasodilatatore n-6-substituierte adenosine.

Also Published As

Publication number Publication date
AU4497285A (en) 1986-01-24
ES544644A0 (es) 1986-09-01
USRE37045E1 (en) 2001-02-06
ES8609359A1 (es) 1986-09-01
US5310731A (en) 1994-05-10
WO1986000310A1 (en) 1986-01-16
IE58495B1 (en) 1993-10-06
IE851565L (en) 1985-12-28
AU590724B2 (en) 1989-11-16
EP0191025B1 (de) 1990-03-07
EP0191025A1 (de) 1986-08-20
CA1285557C (en) 1991-07-02

Similar Documents

Publication Publication Date Title
DE3576345D1 (de) N-6- und 5'-n-substituierte carboxamidoadenosinderivate als herzvasodilatatoren und antihypertensive stoffe und verfahren zur herstellung dieser verbindungen.
DE3581512D1 (de) Verfahren zur herstellung von pyrrolo-(3,4-c)-pyrrolen und neue pyrrolo-(3,4-c)-pyrrole.
DE3777940D1 (de) Verfahren zur herstellung von feinem zirkonoxydpulver.
DE3785806D1 (de) Zaehes hartmetall und verfahren zu seiner herstellung.
DE3683929D1 (de) Harzgebundene magnetische zusammensetzung und verfahren zur herstellung magnetischer gussstuecke daraus.
AT386414B (de) Verfahren zur herstellung des neuen 2'-acetylery- thromycinstearates
DE3480721D1 (de) Verfahren und vorrichtung zur herstellung von einkristallen.
ATE87801T1 (de) Verfahren und vorrichtung zur herstellung von reissverschluessen.
DE3870633D1 (de) Verfahren zur herstellung von butyrolactonen und von butandiolen.
DE3776601D1 (de) Verfahren zur herstellung von p.l.z.t.-pulver.
ATA96986A (de) Verfahren zur herstellung von epipodophyllotoxin und verwandten verbindungen
DE3684511D1 (de) Verfahren zur herstellung von l-threonin und l-isoleucin.
DE3787543D1 (de) Verfahren zur herstellung von 6,13-dihydrochinacridonen und chinacridonen.
DE3684922D1 (de) Verfahren zur herstellung von 2-phenylbenzotriazolen und 2-phenylbenzotriazol-n-oxyden.
DE3875280D1 (de) Verfahren zur herstellung von 9(11)-dehydro-steroidderivaten.
DE3783199D1 (de) Verfahren zur herstellung von 4,4' diaminodiphenylmethan und derivaten davon.
DE3780527D1 (de) Verfahren zur herstellung von 5'-guanyl-saeure.
DE3580120D1 (de) Laeufer und verfahren zur herstellung solcher laeufer.
DE3671246D1 (de) Verfahren zur herstellung von 4-androsten-3,17-dion und 1,4-androstadien-3,17-dion.
ATA200786A (de) Skischuh und verfahren zur herstellung desselben
ATA102986A (de) Verfahren zur herstellung des neuen (-)-1beta|thyl-1alpha-(hydroxymethyl)-1,2,3,4,6,7,12, 12balpha-octahydroindolo(2,3-a) chinolizins und von dessen saeureadditionssalzen
DE3669148D1 (de) Verfahren zur herstellung von 4,4'-dinitrodibenzylen.
LU84495A1 (de) Azolyl-penten-derivate,verfahren zur herstellung dieser verbindungen sowie diese enthaltende biozide mittel
DE3874496D1 (de) Verfahren zur herstellung von 4,4'-dibrombiphenyl.
AT380688B (de) Verfahren zur herstellung von 5-(e)-(2-bromvinyl)-2'-desoxyuridin und seinen derivaten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8315 Request for restriction filed
8327 Change in the person/name/address of the patent owner

Owner name: DISCOVERY THERAPEUTICS, INC., RICHMOND, VA., US

8328 Change in the person/name/address of the agent

Representative=s name: STREHL, SCHUEBEL-HOPF & PARTNER, 80538 MUENCHEN

8327 Change in the person/name/address of the patent owner

Owner name: ADERIS PHARMACEUTICALS, INC. (N.D.GES.D. STAATES D

8318 Patent restricted